Cancer treatment reports, Volume 71, Issues 9-12
National Institutes of Health (U.S.), National Cancer Institute (U.S.), National Cancer Institute (U.S.). Division of Cancer Treatment
U.S. Dept. of Health, Education, and Welfare, Public Health Service, National Institutes of Health, 1987 - Medical
What people are saying - Write a review
We haven't found any reviews in the usual places.
Phase I Clinical Trial of Methylene Dimethane Sul Madon G Grazia B De Bernardi A Cornell M
Other editions - View all
5-fluorouracil administered advanced breast cancer agents assay assessed azacitidine bolus bone marrow breast cancer Cancer Center Cancer Res Cancer Treat Rep carboplatin cell carcinoma cell lung cancer Chemother chemotherapy cisplatin Clin Oncol clinical trials colorectal combination concentration count nadir courses creatinine cycles cyclophosphamide cytotoxic doxorubicin drug etoposide evaluable folinic acid grade high-dose Hospital human idarubicin ifosfamide infusion injection interferon ipomeanol lesions leukemia leukopenia liver lung cancer malignant metastatic methotrexate mg/dl mg/kg mice mifepristone mitoxantrone months myelosuppression National Cancer Institute nausea and vomiting oral partial response patients received patients with advanced performance status pharmacokinetics phase II study phase II trial plasma platelet count prednisone prior chemotherapy Proc ASCO radiotherapy range rats regimen relapse remission renal reported Reprint requests response rate serum Southwest Oncology Group stable disease taxol therapy thiotepa three patients tion tissue toxic effects tumor cells vinblastine vincristine vitro wbc count weeks